Incidental findings on follow-up fluorodeoxyglucose positron emission tomography studies in lymphoma patients: beware the outlier.
Aide
Nicolas
N
Centre for Molecular Imaging, Lung Unit, the Peter MacCallum Cancer Centre, East Melbourne, Australia.
Irving
Louis
L
Hicks
Rodney J
RJ
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D033162:Incidental Findings; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008171:Lung Diseases / Q000139:chemically induced / Q000175:diagnosis; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D049268:Positron-Emission Tomography / Q000379:methods*; D000069283:Rituximab; D014057:Tomography, X-Ray Computed / Q000379:methods*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D019788:Fluorodeoxyglucose F18; D000069283:Rituximab